$SPRY News

Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

Third Point Increases Stake In ARS Pharmaceuticals To 1,000,000 Shares

ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment

ARS Pharmaceuticals Q1 2026 Earnings Call Transcript

ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals Appoints Donn Casale President, Effective June 1

Health Canada Approves ARS Pharmaceuticals' Neffy 2 Mg (Epinephrine Nasal Spray) For The Emergency Treatment Of Allergic Reactions (Anaphylaxis) In Adults And Children Who Weigh 30 kg Or More

FDA Approves ARS Pharmaceuticals Updating Neffy 1 mg Prescribing Information To Remove Age Criteria

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

ARS Pharmaceuticals: Q4 Earnings Insights

ARS Pharmaceuticals Q4 EPS $(0.42) Beats $(0.44) Estimate, Sales $28.087M Beat $25.584M Estimate

Exploring ARS Pharmaceuticals's Earnings Expectations

ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock

ARS Pharmaceuticals To Present Neffy Clinical Data At AAAAI Annual Scientific Meeting

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

ARS Pharmaceuticals Gets Positive Opinion For Expanded Marketing Authorization For EURneffy By EMA's Committee For Medicinal Products For Human Use